Compounds for Cardiovascular & Endothelial Health
Preventive cardiology now talks about residual inflammatory risk — the leftover cardiovascular risk from arterial inflammation even when LDL is low. Here’s how that framing maps onto the compounds people actually research.
How It Works
Even when LDL is driven low, a residual cardiovascular risk persists, attributed to arterial inflammation — the interleukin-1β → interleukin-6 → C-reactive protein (CRP) signalling axis. CANTOS first showed that targeting interleukin-1β with canakinumab as antiinflammatory therapy for atherosclerotic disease lowered cardiovascular events independent of lipids (PMID 28845751). This is context for why anti-inflammatory mechanisms are studied — it is not an endorsement of any compound below for preventing heart attacks.
In the SELECT trial, semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes (PMID 37952131, semaglutide and cardiovascular outcomes in obesity without diabetes). Proposed mechanisms include weight loss, blood-pressure and lipid changes, and reduced systemic inflammation — studied as cardiovascular outcomes, not a cure.
In rodent and cell models, the pentadecapeptide BPC 157 shows pro-angiogenic activity associated with VEGFR2 activation and up-regulation (PMID 27847966) and interacts with the nitric-oxide (L-arginine / L-NAME) system in vascular healing (PMID 30622376). These are PRECLINICAL animal findings only — there are no human cardiovascular outcome trials for BPC-157.
PDE5 inhibitors such as tadalafil act on the nitric-oxide / cGMP pathway that governs vascular tone. A placebo-controlled trial reported that tadalafil improved haemodynamics and arterial stiffness in grade-1 obesity, though not flow-mediated dilation (PMID 36043781); a separate randomized trial examined tadalafil and endothelial dysfunction in erectile dysfunction (PMID 30638829). Endothelial-function endpoints, not cardiovascular event reduction.
In REDUCE-IT, icosapent ethyl (a purified EPA omega-3) reduced cardiovascular risk in statin-treated patients with elevated triglycerides (PMID 30415628, cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia). Note this was a specific prescription EPA formulation — not interchangeable with generic fish-oil supplements, which have shown mixed outcome data.
What the Data Shows
Key Takeaways
- Residual cardiovascular risk persists despite low LDL, and is partly driven by arterial inflammation along the IL-1β → IL-6 → CRP axis (CANTOS, PMID 28845751).
- Semaglutide reduced major adverse cardiovascular events in the SELECT trial in people with obesity but without diabetes (PMID 37952131).
- Icosapent ethyl (purified EPA) reduced cardiovascular events in high-triglyceride statin patients in REDUCE-IT (PMID 30415628).
- Low-dose colchicine reduced cardiovascular events in chronic coronary disease (LoDoCo2, PMID 32865380) and post-MI (COLCOT, PMID 31733140); the FDA approved 0.5 mg colchicine for cardiovascular risk in 2023.
- PDE5 inhibitors like tadalafil act on the nitric-oxide pathway and have been studied for endothelial-function and arterial-stiffness endpoints (PMID 36043781).
- BPC-157 has NO human cardiovascular outcome data — its vascular and angiogenic effects (PMID 27847966, PMID 30622376) are preclinical animal findings only.
- Ziltivekimab (anti-IL-6) lowered hs-CRP in the phase-2 RESCUE trial (PMID 34015342) but has not yet proven a benefit on hard cardiovascular endpoints; the ZEUS outcomes trial is ongoing. It is investigational.
- Generic fish-oil supplements are not interchangeable with the prescription EPA formulation tested in REDUCE-IT, and broader omega-3 outcome data are mixed.
- No compound on this page is shown to "prevent heart attacks" in healthy people — the trials studied specific high-risk populations.
- None of this is individualized treatment guidance; cardiovascular decisions belong with a qualified clinician who can weigh your own risk factors.
Frequently Asked Questions
What is residual inflammatory risk?
Residual inflammatory risk is the cardiovascular risk that remains after LDL cholesterol is lowered, attributed to ongoing arterial inflammation along the interleukin-1β → interleukin-6 → C-reactive protein axis. CANTOS (PMID 28845751) provided proof of concept that targeting this pathway lowers events independent of lipids.
Do GLP-1 agonists like semaglutide have cardiovascular benefits?
In the SELECT trial (PMID 37952131), semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes. This is an outcome studied in a specific high-risk population, not a general claim for healthy people.
Is BPC-157 proven for heart or blood-vessel health?
No. BPC-157’s pro-angiogenic and nitric-oxide-pathway effects (PMID 27847966, PMID 30622376) come entirely from animal and cell studies. There are no human cardiovascular outcome trials for BPC-157, so it should be treated as preclinical research only.
How do PDE5 inhibitors like tadalafil affect the endothelium?
Tadalafil works on the nitric-oxide / cGMP pathway that regulates vascular tone. A placebo-controlled trial (PMID 36043781) found it improved arterial stiffness and haemodynamics in grade-1 obesity, though not flow-mediated dilation — these are endothelial-function endpoints, not cardiovascular event reduction.
Which omega-3 actually reduced cardiovascular events?
In REDUCE-IT (PMID 30415628), the purified-EPA prescription drug icosapent ethyl reduced cardiovascular events in statin-treated patients with high triglycerides. Generic fish-oil supplements are not the same formulation and have shown mixed outcome data.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
This page summarizes published research on cardiovascular and endothelial mechanisms. It does not recommend that any individual take any compound. BPC-157 is preclinical; ziltivekimab is investigational. Cardiovascular decisions belong with a qualified clinician.